Pharmacokinetic Study of Dexmedetomidine After Intra-nasal Dosing in Children

The study will be a prospective study of plasma concentrations after intranasal (1 µg/kg and
2µg/kg) and intravenous (1 µg /kg) DEX to determine the early pharmacokinetics (maximum
concentration (peak) and time to peak) and bioavailability of a single intranasal dose in
pediatric patients.

Dexmedetomidine sedation is commonly utilized at Cincinnati Children's Medical Center (CCHMC)
and other pediatric institutions. This compound is delivered intravenously or intranasally
for sedation in children with and without congenital heart disease. Intranasal DEX, though
very effective for sedation, has significant variability in its onset and peak effect.
Patient care will be significantly improved if factors that determine this variability in
onset and peak effect can be determined. Investigators will determine the important early
clinical variables of peak plasma DEX concentration (Tmax and Cmax) and the 0 - 2 hour
bioavailability of intranasal DEX in children.

Inclusion Criteria:

- Children aged 6 - 48 months (inclusive) scheduled to receive anesthesia for elective
cardiac surgery.

- The subject must be a candidate to receive DEX. A physician member of the Division of
Cardiac Anesthesiology, not involved in the study, will make this decision.

- The subject's legally authorized representative has given written informed consent to
participate in the study.

Exclusion Criteria:

- Post-natal age (PNA) < 6 months

- The subject is allergic to or has a contraindication to DEX

- Severely depressed ventricular function (ejection fraction 30% or less) on
preoperative echocardiogram

- The subject has high risk cardiac conduction system disease at the discretion of the
attending anesthesiologist or cardiologist.

- The subject has a hemodynamically significant coarctation or other left heart outflow
obstruction

- The subject has received digoxin, beta-adrenergic antagonist, or calcium-channel
antagonist on the day of the study

- The subject has received DEX within 1 week of the study date (information obtained
from: parent or Medical record)

- Subject have nasal/respiratory symptoms which in the opinion of the Principal
investigator, may affect intranasal drug absorption.